Sorin Group plans $10 million DOJ settlement
This article was originally published in The Gray Sheet
Executive Summary
Milan-based cardiovascular device company announces March 12 a tentative settlement with the U.S. Department of Justice over a 2006 investigation into its U.S. cardiac rhythm management business unit, Ela Medical Inc. The firm expects a definitive agreement will require a corporate integrity agreement with the DOJ and HHS' Office of Inspector General. Sorin admits no wrongdoing, says no charges were filed, and asserts patient and product safety were not at issue in the investigation. Ela Medical received a subpoena in September 2006 requesting all documents that could show the company "may have provided benefits to persons in a position to recommend purchase of devices" between January 2004 and September 2006
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.